Histopathology and molecular genetics of bladder cancer;Histopathologie und molekulargenetik des harnblasenkarzinoms

Onkologe

Volumn 13, Issue 12, 2007, Pages 1058-1066

  Stoehr, R ^a   Hartmann, A ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Bladder cancer; FGFR3 mutations; Subclassification; Urothelial tumors; WHO classification

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADVANCED CANCER; BLADDER BIOPSY; BLADDER CANCER; CANCER PATIENT; CELL PROLIFERATION; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; MORTALITY; REVIEW; TUMOR BIOPSY; UROGENITAL TRACT TUMOR; WORLD HEALTH ORGANIZATION;

EID: 36948999246     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-007-1278-9     Document Type: Review

References (30)

1. Als AB, Dyrskjot L, Maase H von der et al. (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13: 4407-4414
2. Cappellen D, De Oliveira C, Ricol D et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20
3. Dyrskjot L, Zieger K, Real FX et al. (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13: 3545-3551
4. Dyrskjot L, Zieger K, Kruhoffer M et al. (2005) A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11: 4029-4036
5. Dyrskjot L, Kruhoffer M, Thykjaer T et al. (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exits disregarding histopathological classification. Cancer Res 64: 4040-4048
6. Eble JE, Sauter G, Epstein U, Sesterhenn IA (eds) (2004) Tumours of the urinary system and male genital organs. WHO classification of tumours. IARC Press, Lyon
7. Hartmann A, Schlake G, Zaak D et al. (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62: 809-818
8. Hernandez S, Lopez-Knowles E, Lloreta J et al. (2005) FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11: 5444-5450
9. Hofmann T, Knüchel-Clarke R, Hartmann A et al. (2006) Clinical implications of the 2004 WHO histological classification of non-invasive tumours of the urinary bladder. EAU-EBU Update series 4: 83-95
10. Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27: 361-373
11. Knowles MA, Habuchi T, Kennedy W et al. (2003) Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 63: 7652-7656
12. Krebs in Deutschland: Häufigkeiten und Trends (2006) Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. in Zusammenarbeit mit dem Robert Koch Institut
13. Lopez-Knowles E, Hernandez S, Malats N et al. (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404
14. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP et al. (2007) Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 25: 285-295
15. Obermann EC, Junker K, Stoehr R et al. (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH and FISH analyses. J Pathol 199: 50-57
16. Passos-Bueno MR, Wilcox WR, Jabs EW et al. (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14: 115-125
17. Pich A, Chiusa L, Formiconi A et al. (2002). Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 95: 784-790
18. Sanchez-Carbayo M, Socci ND, Lozano J et al. (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24: 778-789
19. Sauter G, Mihatsch MJ (1998) Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol 185: 3339-3341
20. Seitz M, Zaak D, Knüchel-Clarke R et al. (2005) Harnblasentumoren - Die neue WHO-Klassifikation 2004. Urologe 9: 1073-1084
21. Stoehr R, Zietz S, Burger M et al. (2005) Deletions of chromosome 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 47: 58-63
22. Sylvester RJ, Meijden AP van der, Oosterlinck W et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-475
23. Tsai YC, Nichols PW, Hiti AL et al. (1990) Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Genes Chromosomes Cancer 29: 256-265
24. Aa MN van der, Leenders GJ van, Steyerberg EW et al. (2005) A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 36: 981-986
25. Oers JMM van, Wild PJ, Burger M et al. (2007) FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 52: 760-768
26. Oers JMM van, Adam C, Denzinger S et al. (2006) Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119: 1212-1215
27. Rhijn BW van, Vis AN, Kwast TH van der et al. (2003) Molecular grading of urothelial cell carcinoma with FGFR3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21: 1912-1921
28. Rhijn BW van, Montironi R, Zwarthoff EC et al. (2002) Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198: 245-251
29. Wild PJ, Herr A, Wissmann C et al. (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11: 4415-4429
30. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725